AOA Dx Secures $17 Million in Series A: LongeVC Backs the Future of Early Cancer Detection

At LongeVC, identifying and supporting transformative innovations remains central to our ethos. Our ongoing involvement with AOA Dx is a prime example of this commitment. A biotech trailblazer, AOA Dx is on a mission to bring about groundbreaking changes in early cancer diagnostics—and not just for ovarian cancer.

AOA Dx recently celebrated the successful closure of a remarkable $17 million funding round. This isn't their first win. Several investors have now placed their faith in AOA Dx for the second time, underscoring its consistent achievements over the past year. Their pioneering work in glycolipids and tumor marker gangliosides, through the state-of-the-art GlycoLocate™ platform, promises to redefine the landscape of early cancer detection.

The stakes are high. With ovarian cancer often slipping under the radar in its early stages, the potential of AOA Dx's platform extends hope for enhanced survival rates and better patient outcomes. But as Oriana Papin-Zoghbi, CEO and Co-Founder of AOA Dx, has highlighted, their focus extends beyond ovarian cancer, marking new frontiers in cancer research.

Garri Zmudze, co-founder and managing partner of LongeVC, expresses our sentiment best: “We're proud to have backed Oriana and her team at AOA Dx since 2022. Their recognition as a Bloomberg New Economy Catalyst speaks volumes about their monumental contribution to medical science. We firmly stand by AOA Dx as a luminary in early cancer diagnostics and are eager to witness the growth and diversification of their GlycoLocate™ platform.”

Join us in championing AOA Dx as they etch a new chapter in cancer diagnostics.

Read the Full AOA Dx article:
Announcement Partner News